

**Brilliant Violet 510™ anti-mouse CD19**

**Catalog # / Size:** 1177730 / 500 µl  
1177725 / 125 µl

**Clone:** 6D5

**Isotype:** Rat IgG2a, κ


**Immunogen:** Mouse CD19-expressing K562 human erythroleukemia cells

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 510™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** Lot-specific



C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 510™ (filled histogram) or rat IgG2a, κ Brilliant Violet 510™ control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunofluorescence<sup>7</sup>.

- Application References:**
1. Shoham T, *et al.* 2003. *J. Immunol.* 171:4062. (FC)
  2. Goodyear CS, *et al.* 2004. *J. Immunol.* 172:2870. (FC)
  3. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306. (FC)
  4. Andoniou CE, *et al.* 2005. *Nat. Immunol.* 6:1011. (FC)
  5. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366. (FC)
  6. Phan TG, *et al.* 2007. *Nat. Immunol.* 8:992. (FC)
  7. Hayashida K, *et al.* 2008. *J. Biol. Chem.* 283:19895. (IF) [PubMed](#)

8. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  9. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
  10. Stadnisky MD, *et al.* 2011. *Blood.* 117:5133. (FC) [PubMed](#)
  11. Perlot T, *et al.* 2012. *J. Immunol.* 188:1201. (FC) [PubMed](#)
- 

**Description:** CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

- Antigen**
- References:**
1. Fearon DT. 1993. *Curr. Opin. Immunol.* 5:341.
  2. Krop I, *et al.* 1996. *Eur. J. Immunol.* 26:238.
  3. Krop I, *et al.* 1996. *J. Immunol.* 157:48.
  4. Tedder TF, *et al.* 1994. *Immunol.*